Quarta-Rad reported $0.245 million in net sales for the year ended December 31, 2025, driven by strong growth in its AI software product Sellavir, and recorded a net loss of $0.257 million, or $(0.02) per share. Revenue rose substantially year-over-year while the company continued to operate with a slim cost structure and focus on commercialization of AI offerings. Management cited the transition from legacy radiation device sales toward AI software and a recent ISV partnership to expand distribution.
Financial Highlights
- Sales - Total sales, net: $0.245 million, up 129.4% from $0.107 million in 2024.
- Gross Profit: $0.102 million (compared with $0.040 million in 2024).
- Operating Income: $(0.291) million (reported as net loss from operations for 2025).
- Net Income: $(0.257) million for the year ended Dec 31, 2025 (versus $(0.217) million in 2024).
- Loss per share — basic and diluted: $(0.02); weighted average shares outstanding 15,883,222.
Business Highlights
- Revenue mix and product focus: The company shifted emphasis from legacy radiation device sales to AI software, with Sellavir driving the bulk of 2025 revenue.
- Sellavir traction: Sellavir revenue rose 487% year-over-year to $235,000 in 2025, substantially contributing to total company sales growth.
- Product commercialization: Management is prioritizing commercialization of CenterEye AI for contact centers, targeting integrations with Genesys, NICE CXone, and Avaya platforms.
- Partnership development: In January 2026 the company executed an ISV agreement with Genesys Cloud to integrate CenterEye and broaden market access.
- Operating model: The company maintains a lean operational footprint — one part-time officer supplemented by contractors for development and marketing — with no near-term hiring planned.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.